News & Events zu Iambic Therapeutics, Inc. Common Stock (IAM)IAMIambic Therapeutics, Inc. Common Stock

Iambic Therapeutics Updates Clinical Data for IAM1363

Iambic Therapeutics announced updated clinical data for IAM1363, a selective and brain-penetrant HER2 tyrosine kinase inhibitor, TKI, from its ongoing Phase 1/1b clinical trial. The data, which showed durable anti-tumor activity, intracranial responses and a favorable tolerability profile in heavily pretreated participants with HER2-altered advanced cancers, were presented in a poster at the European Society for Medical Oncology, ESMO, Congress 2026 in Madrid on October 23, 2026. Key highlights: IAM1363, now in a Phase 1/1b study, was designed using Iambic's molecular superintelligence platform and brought to clinical development in approximately two years; Data presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse events, and dose modifications; More than half of participants dosed at 960 mg remain on study with some participants on treatment beyond one year; Intracranial responses were observed in participants with HER2-positive breast cancer who have previously received T-DXd and tucatinib

City Therapeutics and Iambic Therapeutics Successfully Debut in Market

Biotech listings continued to build momentum as City Therapeutics and Iambic Therapeutics made their market debuts, highlighting investor interest in RNA based therapies and AI enabled drug development.LATEST IPOS AND DIRECT LISTINGS:City Therapeuticsopened on October 16 at $23. The clinical-stage biotechnology company, that says it is "developing the next generation of RNA interference therapeutics," priced its upsized initial public offering of 11.11M shares of its common stock at a public offering price of $18.00 per share. City's lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases.Iambic Therapeuticsopened on October 15 at $16.15. The clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform priced 9.375M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range.Amaeroopened on October 15 at $4.10. The U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing and advanced manufacturing priced 4,705,883 shares of its common stock at an initial public offering price of $4.25 per share. Amaero intends to use up to approximately $10M of the net proceeds of the offering to purchase capital equipment over the next 12 months with the remaining proceeds to be used for general corporate purposes, including working capital, operating expenses, and research and development.RECENT SPAC IPOS:TCGX Acquisition Corp. IIopened on October 16 at $11.20. The company had priced its initial public offering of 10M shares at a price of $10.00 per share. TCGX is a special purpose acquisition company that intends to focus its search on the healthcare and healthcare-related industries, particularly in the life sciences and medical technology sectors.PERFORMANCE:Prices as of 11 am ET on Monday, October 19 -City Therapeutics – down about 6% at $21.17;Iambic Therapeutics – down almost 29% at $16.94;Amaero – up about 28% at $5.75.RECENT IPOS TO WATCH:ADARx Pharmaceuticalsis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include FireFly Robotics, Anthropic, Nscale, Altera, and Brooks Automation.Clickto see upcoming IPO calendar on TipRanks.FireFly Robotics, which designs and manufactures autonomous, all-electric robotic systems for turf and grounds environments, announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public direct listing of its common stock. The company is not selling any shares and will not receive any proceeds in the direct listing.Anthropicis now planning to hold its IPO in November, which is later than the October listing expected by investors, The Wall Street Journal's Corrie Driebusch, Anissa Gardizy, and Kate Clark, citing people familiar with the matter. The report states that a delayed listing would allow the company to share its Q3 results and show its strong competitive position. Anthropic also intends to meet with investors in the coming days, and the meetings are expected to help the company and its bankers gauge investor appetite for the offering, WSJ noted.Nscale Limitedhas filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Alteraannounced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automationannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.

Iambic Therapeutics Prices 9.375M Shares at $16.00

Iambic Therapeutics, a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, priced 9.375M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. JPMorgan, Jefferies, BofA and Citi are acting as joint book running managers for the offering.